Q-omics provides the consensus-scored HBZP1 profile across patient tissues and cancer cell-line models. HBZP1 expression is associated with patient survival in 8 of 34 cancer types, with the highest sampling consensus in STAD. Among the 18 cancer types available for tumor–normal comparison, HBZP1 is differentially expressed in 1, with the highest sampling consensus in LUSC. Additionally, HBZP1 RNA expression shows 5,545 significant gene co-expression associations, with the highest sampling consensus in LGG. Together, these results highlight STAD, LUSC, and LGG as cancer lineages where HBZP1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HBZP1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HBZP1 survival associations across molecular data types. HBZP1 RNA expression shows survival associations in the most cancer types (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HBZP1 RNA expression–survival associations across cancer types. High HBZP1 expression shows unfavorable associations in STAD, KIRP, UCEC, LUSC, LIHC and UCS. The STAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify STAD as the clearest survival context for HBZP1 RNA expression.
This table summarizes HBZP1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for HBZP1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HBZP1 shows lower tumor expression in LUSC. The LUSC box plot shows higher HBZP1 RNA expression in normal versus tumor tissue (log2 FC = −0.019, t-test p = .011).
This table shows molecular features associated with HBZP1 in patient tissues and cancer cell lines. In patient samples, HBZP1 shows the broadest associations at the RNA and protein expression levels, with LGG recurring as the lineage with the largest associated feature set.
